Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 1000K 2026-06
Agenus USD -199.08M 22.15M 2026-06
Amgen USD 11.69B 6.9B 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Celldex Therapeutics USD 714.56M 258.34M 2026-06
CSL USD 5.7B 2.82B 2025-12
Eli Lilly USD 10.52B 496M 2026-06
Gilead Sciences USD 3.95B 19.57B 2026-06
GlaxoSmithKline GBP 5.8B 468M 2026-06
Glaxosmithkline GBP 5.34B 3.83B 2026-03
Incyte USD 973.64M 4.65B 2026-06
Intrexon USD 61.56M 26.1M 2024-06
J&J USD 17.83B 388M 2026-06
Jiangsu Hengrui CNY 5.52B 604.29M 2026-03
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
MacroGenics USD 42.87M 21.68M 2026-06
Merck EUR 4.34B 249M 2026-06
Merck USD 15.77B 2.4B 2026-06
Northwest Biotherapeutics USD 11.39M 120.04M 2026-03
Novartis USD 10.2B 912M 2026-06
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 85.19B 4.91B 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Veracyte USD 126.36M 6.37M 2026-06